Onyx Biotec Share Price

Onyx Biotec Limited was incorporated as Onyx Biotec Private Limited, pursuant to a Certificate of Incorporation dated May 13, 2005 issued by the Registrar of Companies, Punjab, H.P. Chandigarh. Further, Company converted into a Public Limited and the name was changed to Onyx Biotec Limited and a fresh Certificate of Incorporation dated July 23, 2024 was issued by the Registrar of Companies, Central Processing Centre.Onyx started its operation in pharmaceutical industry with sterile water for injections with capacity of 2 lacs units per day in year 2010. Since then, Onyx is engaged in Manufacturing of Pharmaceutical Products such as sterile water ampoule, dry injection, dry syrup etc. to major corporations, which includes the top pharma companies. Presently, the Company manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas. The core business is on providing endtoend product development and manufacturing solutions to clients. The service include preparation and filing of regulatory dossiers in the Indian and global markets.The Company has Unit I and Unit II manufacturing plants in Solan District of Himachal Pradesh. Unit1 was started in 2010, for the production of Sterile Water for Injections (SWFI) ampoules in FFS technology. Having 6 production machines, and a list of esteemed customers like Aristo, Mankind, Dr Reddys, Sun Pharma, Macleods etc, it has established itself as a major player in this field. The Company later on, enhanced the capacity expansion from 130 million unit per annum to 230 million units per annum capacity in 201718.Unit2 came into manufacturing in 2023, involved in the manufacturing of Dry Powder Injections, and Dry Powder Syrup (Cephalosporin) range. It was granted WHO GMP certificate by the CDSCO in May 2024.48,10,000 equity shares of Rs 10/ were allotted pursuant to IPO by raising Rs 29.34 crores via offer for sale on November 19, 2024.